An increasing number of studies have shown a critical role for the membrane attack complex, synthesized on activation of the terminal pathway of the complement system, in causing demyelination and neuronal death in neurodegeneration. The aim of this study was to develop a strategy to increase the resistance of neurons to complement damage by modulating the expression of membrane complement regulatory protein CD59, the only inhibitor of the terminal pathway of the complement cascade. We exploited our recent finding that CD59 expression is regulated by the neural-restrictive silencer factor (REST) and designed a novel REST-derived peptide (REST5) containing the nuclear localization domain of the wild-type protein. The effect of REST5 and the mechanism by which it modulates CD59 expression were modelled in neuroblastoma cells transfected with expression constructs, and then confirmed in human neurons differentiated from neural progenitor cells. REST5 increased the expression of CD59 in neurons by fivefold and protected them from complement-mediated lysis spontaneously triggered by neurons. As a source of complement, we used either human serum or conditioned medium from primary human oligodendroglia. This study brings new insight into immunopharmacological research that may serve to inhibit neuronal death triggered by the terminal pathway of complement activation.
Introduction
The complement system is a key component of innate immunity, having a central role in defence against pathogens. 1 It is also a powerful drive to initiate inflammation and can, if unregulated, cause pathology leading to severe tissue damage. Complement has been implicated in various human neurodegenerative disorders, such as Alzheimer's disease (AD), Huntington's disease, Pick's disease and multiple sclerosis (MS). 2 Although viewed for years as an immunoprivileged organ, the central nervous system contains and synthesizes many components of the immune system. Cultured and primary neurons, astrocytes, microglia, oligodendroglia and endothelial cells were shown to produce all the complement components of both alternative and classical pathways, and also the proteins involved in the terminal pathway forming membrane attack complex (MAC). [3] [4] [5] [6] [7] [8] Thus, the local production of complement components in the brain ensures the complete functionality of the complement system without the need for infusion of plasma-derived complement proteins.
Inflammation and complement systems as a generator of proinflammatory molecules such as C3a and C5a have previously been thought of as detrimental in the pathophysiology of neurodegenerative diseases. However, emerging genetic data, magnetic resonance imaging studies, immunopathological evidence and in vivo studies in animal models 9, 10 challenge this simplistic view. Evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in neurodegenerative diseases such as MS and AD, thus explaining some of the results from recent trials of anti-inflammatory agents. Besides the proinflammatory role of complement component C5a, it was recently shown that this anaphylatoxin may also have a protective role in AD brain through the activation of neuroprotective mitogen-activated protein kinases. 11 In support of this, animals genetically deficient in complement component C5 were found to be more susceptible to hippocampal excitotoxic lesions. 12 These findings suggest a novel noninflammatory role for C5a in modulating neuronal responses to excitotoxins. However, several studies have unambiguously shown a critical role for MAC synthesized on activation of the terminal pathway of the complement system in causing demyelination in humans and experimental autoimmune encephalomyelitis and MS in animal models. 13, 14 CD59, a ubiquitously expressed membrane-bound complement regulatory protein (mCReg), exists to protect self-cells from damage caused by the activation of the complement cascade by blocking the formation of MAC. 1 There is very little information regarding the expression of mCReg in neuronal cells. Studies to date suggest that cultured primary neurons express only low levels of CD59 and CD46. 15, 16 CD55 was not detectable by immunohistochemistry staining. 17 In contrast, oligodendroglia, the main function of which in higher vertebrates is to insulate axons exclusively in the central nervous system, abundantly express CD59 and, although at a lower level, CD55 and CD46. 18 Furthermore, neuronal cell lines and primary neurons were shown to activate the complement cascade spontaneously, which, together with the very low levels of CD59, suggest their vulnerability to MAC lysis. 19 Therefore, it is likely that CD59 might be an important resistance factor in protecting against MAC-mediated demyelination and lysis. Thus, targeting the expression of MAC regulator CD59 seems an attractive approach for protecting neurons from complement-mediated degeneration.
The main objective of this study was to develop a strategy to increase the resistance of neurons to complement damage by modulating the expression of CD59. We achieved this by further exploiting our recent finding on the regulation of the expression of CD59 by neural-restrictive silencer factor (REST), which allowed us to design a novel peptide that overexpressed CD59 in neurons and protected them from complement-mediated lysis.
Materials and methods

Cells and treatment
ReNcell VM human neural progenitor cells 20 were obtained from Millipore UK (Watford, Hertfordshire, UK), and were expanded in T25-cm 2 tissue culture flasks precoated with laminin (Sigma-Aldrich, Gillingham, UK) in Dulbecco's modified Eagle's medium:F12 medium containing B27 neural cell supplement mix (Invitrogen, Paisley, UK), L-glutamine (2 mM, Invitrogen), heparin (10 Units ml À1 , Sigma-Aldrich), gentamicin (50 mg ml À1 , Invitrogen), Basic fibroblast growth factor (bFGF) (10 ng ml À1 , Invitrogen) and epidermal growth factor (EGF) (20 ng ml
À1
, Sigma-Aldrich). Cells were differentiated (REN neurons) over a 2-week period in the above medium, but without bFGF and EGF. 20 Primary human oligodendroglia (TCS CellWorks, Buckingham, UK) were recovered and maintained in 2 ml of oligodendroglia medium in a T25-cm 2 tissue flask according to the supplier's protocol. The culture medium was collected for complement lysis assay twice a week and replaced with fresh one until cells were viable. Human neuroblastoma cell line IMR32 (European Collection of Animal Cell Cultures, Salisbury, UK) was maintained in RPMI 1640 with 10% heat-inactivated fetal calf serum, supplemented with glutamine, penicillin and streptomycin (Invitrogen). All cells in culture were maintained at 37 1C in a humidified atmosphere of 95% air/5% CO 2 .
REN neurons were treated with 10 mM His-TAT-REST5 or a control His-TAT-NLS peptide (Bio-Synthesis, Lewisville, TX, USA) for 8, 16 or 24 h. His-TAT-REST5 peptide ( Figure 1 ) comprises a His-tag, HIV-1 transactivator protein transduction domain (TAT) and zinc-finger domain 5 (REST5) from REST protein, separated from each other by three Gly residues to ensure flexibility of each of these domains. 21 In the control His-TAT-NLS peptide (Figure 1 ), the REST5 domain was replaced by the classical nuclear localization signal (NLS) for delivery of RNA polymerase II through an importin-a1 receptor.
Purification of neurons and separation of cytoplasmic and nuclear proteins To obtain high-purity neurons (497%), we used magnetic beads coated with anti-human CD90 (Gentaur Europe, Brussels, Belgium), following the supplier's protocol. To separate the cytoplasm from nuclei, purified neurons bound to beads were lysed by incubation on ice for 5 min with phosphate-buffered saline containing 0.3% NP-40. Beads were removed and the lysate was centrifuged for 3 min at 2000 g. The supernatant contained the cytoplasm of neurons, whereas nuclei formed a pellet. Nuclei were lysed with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). Protein concentration in each sample was determined by the Micro BCA Protein Assay Kit (Perbio Science UK, Cramlington, Northumberland, UK).
Dot-blot analyses
Dot-blots were carried out using standard protocols. Polyclonal anti-REST antibody, C-15, specific for the C-terminus of the protein (catalogue number sc-15120, Santa Cruz Biotechnology, Santa Cruz, CA, USA), was used to detect the full-length REST on dot-blots from different cell types. For detection of the REST5 peptide, a monoclonal mouse antiHis antibody (clone HIS.H8, catalogue number 05-949, Millipore) against the N-terminal His-tag was used. To control for the amount of sample loaded, blots were stained with a polyclonal anti-b-actin antibody (catalogue number ANA54590, Cambridge Bioscience, Cambridge, UK). Analyses were carried out as previously described. 22 Design of peptide for overexpression of CD59 To test the effect of REST-derived peptide on the expression of CD59, a pDR2DEF1a-based construct for expression in mammalian cells was designed. The sense (5 0 -CTAGAGCCA CCATGATGCATCATCATCATCATCATGGTGGTGGTTATAAA TGTGAACTTTGTCCTTACTCAAGTTCTCAGAAGACTCATC TAACTAGACATATGCGTACTCATTGAG-3 0 ) and antisense (5 0 -GATCCTCAATGAGTACGCATATGTCTAGTTAGATGAGT CTTCTGAGAACTTGAGTAAGGACAAAGTTCACATTTATAAC CACCACCATGATGATGATGATGATGCATCATGGTGGCT-3 0 ) oligonucleotides were synthesized (Biomers.net GmbH, Ulm, Germany) and annealed, leaving the XbaI and Bam HI overhangs at their 5 0 and 3 0 ends, respectively, for ligation into an appropriately digested pDR2DEF1a vector. This construct expresses a peptide comprising six His residues, three Gly residues and the REST5 zinc-finger domain ( Figure 1 ). A control plasmid in which the REST5 domain was replaced by the NLS (Figure 1 ) was also designed (sense: 5 0 -CTAGAGCC ACCATGGCCCATCATCATCATCATCATGGCGGCGGCCCTA AGAAGAAGAGAAAGGTGTGAG-3 0 ; antisense: 5 0 -GATCCTC ACACCTTTCTCTTCTTCTTAGGGCCGCCGCCATGATGATG ATGATGATGGGCCATGGTGGCT-3 0 ). The constructs were transfected into IMR32 cells using Effectene reagent (Qiagen, Crawley, West Sussex, UK) and cells were selected and maintained in medium containing 100 mg ml À1 hygromycin B (Invitrogen).
Flow cytometry
The effect of the REST5 expression construct and REST5 peptide on the expression of CD59, CD55 and CD46 at the protein level was assessed by staining neuroblastoma cells or neurons (3 Â 10 5 ) with mouse monoclonal antibodies MEM43 (catalogue number ab9182), BRIC216 (catalogue number ab33111) and MEM258 (catalogue number ab789), all from Abcam plc, Cambridge, UK, against CD59, CD55 and CD46, respectively, and analysing by flow cytometry. A detailed description of this procedure was given previously. 23 All measurements were made at least in duplicate and each experiment was replicated twice. Results were combined and statistically analysed by Student's t-test. A P-value o 0.05 was considered to show statistically significant differences.
Chromatin immunoprecipitation (ChIP)
The IMR32 cells transfected either with the REST5 or NLS expression construct were analysed as previously described, 22 using Magna ChIP A kit (Millipore). Immunoprecipitation was carried out with rabbit polyclonal anti-Sp1 (catalogue number 17-601, Millipore), rabbit polyclonal anti-AP2 (catalogue number ab52222, Abcam), sheep polyclonal anti-CPBP (catalogue number AF3499, R&D Systems Europe, Abingdon, UK) or polyclonal anti-REST (C-15) (catalogue number sc-15120, Santa Cruz Biotechnology). Nonimmune rabbit IgG supplied in the Magna ChIP A kit was used as a control for the background of these experiments. The naked co-immunoprecipitated DNAs were then used as templates in quantitative PCR assays as described below. Statistical significance of differences between experimental groups was assessed using an unpaired, two-tailed Student's t-test.
Quantitative PCR Total RNAs from IMR32 cells and REN neurons treated as described above were purified using the GenElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich). cDNAs were synthesized using TaqMan Reverse Transcription reagents (Applied Biosystems, Warrington, UK), and amplification was carried out on a Mini Opticon Real-Time PCR Unit (Bio-Rad, Hemel Hempstead, Herts, UK) using iQ SYBR Green Supermix (Bio-Rad) and primer pairs described in Table 1 . RNA expression levels were calculated using the comparative C t method (DDC t ). At least two independent experiments were carried out for each mRNA, and Student's t-test was applied to calculate significance in changes of the expression pattern. In a similar manner, we quantified the binding of different transcription factors to the cd59 promoter. Immunoprecipitated DNAs were used as templates (10 ng per reaction) in a quantitative assay with a primer pair for detection of the responsive element within the cd59 promoter. 23 The C t value calculated for the input DNA used in ChIPs was used to normalize the cell number. Two independent analyses of immunoprecipitated DNAs were carried out for each antibody.
Complement lysis assay
Lysis was assessed by measuring lactate dehydrogenase (LDH) release using a Colorimetric Cytotoxicity assay kit (Oxford Biomedical Research, Oxford, MI, USA) as previously described. 23 Different dilutions of normal human serum (NHS) or conditioned medium from primary human oligodendroglia were used as the source of complement. As negative controls for the complement-mediated lysis, we either inactivated complement by heat treatment (15 min at 56 1C) of NHS and the conditioned medium or depleted the NHS/conditioned medium of C8 using a monoclonal affinity column. In experiments with CD59 blocking, excess of Fab fragments (10 mg ml À1 ) generated from MEM43 mAb against CD59 (ImmunoPure Fab preparation kit, Perbio Science UK) was preincubated with cells for 30 min at 37 1C and washed twice with phosphate-buffered saline; thereafter, serum/conditioned medium was added at appropriate dilutions. All experiments were carried out in triplicate for each condition. The percentage of lysed cells was calculated using the following formula:
% Lysis ¼ ððmeasured LDH release À spontaneous releaseÞ =ðmaximum release À spontaneous releaseÞÞÂ100
The experiment was replicated twice and data were analysed by Student's t-test.
Results
Modelling of a peptide for upmodulation of CD59 expression
To test whether the previously reported mechanism for suppression of CD59 expression by the transcriptional suppressor REST 23 could be explored to design a peptide capable of enhancing neuronal resistance to complement, a plasmid was engineered to inhibit the delivery of endogenous REST to the nucleus (Figures 1a and b) . The plasmid encoded a peptide comprising the zinc-finger domain 5 of REST (REST5) essential for nuclear delivery through a REST-specific receptor, 24, 25 and a His-tag to allow discrimination between endogenously expressed REST and REST5. A control construct in which the REST5 domain was replaced by the classical NLS for delivery through importin-a1 was also designed (Figures 1b) . Therefore, the expressed control peptide should not compete with endogenous REST for nuclear delivery. As primary neurons are difficult to transfect, plasmids were tested in IMR32 neuroblastoma cells that, similar to primary neurons, express full-length REST. 23 Transfected cells were selected and maintained in the presence of hygromycin B in culture medium. Dot-blot analysis of REST and REST5 in nuclear extracts unambiguously showed that expression of REST5 in IMR32 cells resulted in a 12-fold decrease in the amount of full-length REST delivered into the nuclei (Figures 2a) . The control NLS peptide was delivered within the nuclei with a similar efficiency to that of REST5; however, it did not affect the nuclear delivery of endogenous REST. ChIP with antibodies against transcription factors previously shown to be involved in regulation of cd59 expression 23 confirmed that this REST5-mediated depletion of endogenous REST in nuclei allowed the binding of transcriptional activators CPBP, Sp1 and AP2 within the responsive promoter sequence of the cd59 gene (Figures 2b).
Treatment with REST5 yielded a fivefold increase in the expression of CD59 at both mRNA and protein levels in IMR32 (Figures 3a and b) . Expression of the other two mCReg, CD55 and CD46, was not affected by the REST5 peptide. Although expression of CD55 was detectable at the mRNA level, it was negligible at the protein level, suggesting no role for this protein in the protection of neurons from complement-mediated lysis. It has been previously shown that fetal human neurons can spontaneously activate the classical pathway of complement cascade without any additional stimuli, resulting in susceptibility to complement lysis. 17 The alteration in the expression of CD59 led to the protection of IMR32 cells from spontaneously triggered complement lysis (Figure 3c ). Around threefold less cells transfected with the REST5 expression plasmid were lysed at the maximum serum concentration compared with cells transfected with the control construct or nontransfected cells. Fab fragments from CD59-blocking antibody were used in control experiments, which resulted in equal lysis in the three cultures, showing that the increased neuronal resistance to complement damage is a result of CD59 upregulation.
REST5 peptide increases the expression of CD59 in human neurons
Having shown that plasmid expressing REST5 transfected into IMR32 protected cells from complement lysis, a peptide was synthesized comprising a His-tag, HIV-1 transactivator 
F, indicates forward primer and R, indicates reverse primer.
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protein transduction domain (TAT) and REST5 sequence (His-TAT-REST5), separated from each other by three Gly residues to ensure flexibility/functionality of each of these domains 26 ( Figure 1b) . The TAT domain efficiently delivers cargo molecules to the cytoplasm in a wide range of species, including human. 27 A peptide comprising His-TAT-NLS domains was used as control. When neurons were exposed to His-TAT-REST5 (REST5) peptides, the peptide was detected in nuclear extracts within 2 h and accumulation increased through 4 h, slowly decreasing thereafter (Figure 4a ). The control NLS peptide was delivered to nuclei with similar efficiency to that of the REST5 peptide. Human neurons were treated with these peptides every 4 h over a period of 24 h. Samples were taken every 8 h and analysed for the presence of endogenous REST in nuclei (Figure 4b ). Densitometric analysis of dot-blot data for endogenous REST showed a decrease of around 50% within the first 8 h of REST5 treatment. However, this was associated with only a slight upregulation of CD59 mRNA expression and no effect on CD59 protein at this time (Figures 5a and b) . At 16 h, endogenous REST was decreased eightfold compared with controls, and this was sustained at 24 h (Figure 4b ). At these time points, the expression of CD59 at both mRNA and protein level was increased fivefold (Figures 5a, b) .
REST5 protects neurons from complement-mediated damage
Once we established the optimum treatment of human neurons with the REST5 peptide, which results in a fivefold overexpression of CD59, we tested the effect of this treatment on the expression of other mCReg proteins (Figure 6a ). The REST5 peptide was added every 4 h over a period of 16 h. Expression of CD46 was not affected during the course of this treatment and CD55 remained negligible. However, as a result of increased CD59 expression by the REST5 management, we observed a substantial increase in the protection of neurons from complement-mediated killing spontaneously triggered by neurons (Figure 6b ). Neurons treated with REST5 had around 2.5-fold less lysed cells by complement sourced from serum, compared with cells treated with the control NLS peptide or nontreated ones. In control experiments, CD59 was preblocked by Fab fragments derived from MEM43-blocking monoclonal antibody. This resulted in an equal lysis of neurons treated with REST5, control NLS peptides or nontreated. These data show that the increased neuronal resistance to complement damage conferred by REST5 is a result of CD59 upregulation.
Our next step was to study whether complement components synthesized locally from brain cells could lyse neurons and whether the REST5 peptide confers resistance to eventual complement-mediated damage (Figure 6c ). We carried a complement lysis assay with REN human neurons similar to that presented in Figure 6b ; however, as a source of complement, we used conditioned medium from primary human oligodendroglia, cells that were shown to synthesize all components of the complement system at both mRNA and protein levels. 8 Indeed, the conditioned medium was capable of lysing neurons. This damage was inhibited by the REST5-mediated upmodulation of CD59 expression by B2.5-fold in comparison with the control treatment with the NLS peptide. Control experiments with preblocking of CD59 in both neuronal cultures showed that the upregulated CD59 was responsible for the observed neuroprotection in our in vitro assay system, proving that neuronal lysis was a result of the activation of the terminal pathway of complement cascade.
Discussion
The critical role of the complement system and particularly of MAC in neuronal death in diverse neurodegenerative diseases is now much better understood. 10, 13, 14 Although oligodendroglia, fetal astrocytes and astrocyte cell lines are well protected from complement damage by an abundant expression of mCReg, 18 neurons are particularly susceptible to MAC attack because of the low expression of CD59 and CD46 on their surface. 15 To increase the resistance of neurons to complement-mediated damage, we designed a new strategy to upmodulate the expression of CD59 by targeting REST on the basis of our recent demonstration that REST has a key role in the regulation of cd59 gene expression. 23 Zinc-finger domain 5 of REST (REST5), essential for the nuclear delivery of the protein, 25 either expressed in IMR32 neuroblastoma cells or added as a synthetic peptide designed for uptake into neurons, successfully competed with endogenous REST for the REST-specific nuclear translocation receptor 24 ( Figures 2-4 ). This resulted in the removal of endogenous REST from the cd59 promoter and recruitment of transcriptional activators CPBP, Sp1 and AP2, previously shown to be involved in the modulation of CD59 expression. 23 This interplay between activators and inhibitors of CD59 transcription yielded a fivefold upregulation of the expression of CD59 and markedly decreased the susceptibility of both IMR32 and neurons to complement-mediated damage spontaneously triggered by neurons (Figures 3 and 6) . We observed that 8 h after beginning REST5 treatment, the amount of endogenous REST in nuclei was reduced by around 50% ( Figure  4 ). This was sufficient to observe a significant upmodulatory effect on the expression of CD59 at the mRNA level (B40%). However, longer time was needed to start accumulating more CD59 protein and reach the maximum effect of a fivefold increase in CD59 expression ( Figure 5 ). Flow cytometry analysis did not detect any significant expression of CD55 protein in both IMR32 cells and neurons differentiated from human neural progenitor cells. This observation is in concordance with an earlier study 17 in which investigators failed to detect the expression of CD55 by immunohistochemical staining of primary human neurons.
To deliver the REST5 peptide to the cytoplasm of human neurons, a TAT domain was added to the N-terminus. This enabled efficient cell uptake and nuclear delivery of the peptide and a subsequent reduction in endogenous REST in the nucleus, as the REST5 competed for nuclear translocation through the REST-specific nuclear receptor (Figure 4) . The endogenous REST protein is reported to have a relatively short half-life in embryonic stem cells (2 h) and neural stem cells (1 h). 28 Improving the stability of the REST5 peptide might further improve the efficiency of the removal of endogenous REST from the cd59 promoter to increase gene expression.
The strategy proposed here for upregulation of CD59 expression would presumably affect the expression of other genes regulated by REST. These targets include a number of genes that require degradation of REST to initiate neuronal differentiation. 29, 30 Therefore, the mechanism of action of the peptide described here suggests that treatment with REST5 should not result in neuronal dedifferentiation. However, further genome-wide studies, such as microarray expression analysis, are necessary to determine any unwanted side effects that this peptide might have on neurons.
Our complement lysis data using conditioned medium from oligodendroglia ( Figure 6 ) are in agreement with those from previous study showing that oligodendroglia synthesize all components of the complement cascade, 8 and further support the hypothesis that the brain locally produces a functional complement system that could be an important mediator in a number of events related to neurodegenerative diseases. Neurons are particularly sensitive to effects driven by the complement because of their very weak protection from complement attack compared with the rest of the central nervous system cells. 31 Although targeting the complement system in different neurodegenerative diseases has been proposed as a very prospective strategy, 32 such an approach requires careful consideration because a number of studies have suggested that certain components generated during complement activation (for example, C5a) are actually of benefit, at least in animal models of MS and AD. 11, 12, 33 The strategies described here cause an upregulation of CD59 on the neurons through mechanisms that are very clearly defined. By increasing the expression of CD59, formation of lytic MAC is inhibited, whereas generation of early activation products, including C5a, which, for example, might contribute to plaque clearance in AD, is unimpeded. Targeting MAC in this way is thus an exceptionally attractive approach. However, further studies are needed to understand the exact role of each component of the complement system in human neurodegeneration to ensure the best choice of therapeutic target. The strategy pioneered here should be further extended in an in vivo animal model to better understand any side effects that the REST5 peptide may have.
